{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,7,30]],"date-time":"2025-07-30T16:29:04Z","timestamp":1753892944302,"version":"3.41.2"},"reference-count":27,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2023,6,16]],"date-time":"2023-06-16T00:00:00Z","timestamp":1686873600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100012166","name":"National Key Research and Development Program of China","doi-asserted-by":"publisher","award":["2021YFC2301604"],"award-info":[{"award-number":["2021YFC2301604"]}],"id":[{"id":"10.13039\/501100012166","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Public Health"],"abstract":"<jats:p>In China, adverse events following immunization (AEFI) are reported by the China AEFI Surveillance System (CNAEFIS). Serious AEFI, including deaths, are mandatorily reported and are evaluated for causality by province-or prefecture-level panels of experts. Yeast-derived HepB is the most widely used HepB in China for infants. However, the information about the death of infants caused by HepB is unclear. The CNAEFIS data on deaths following HepB from 2013 to 2020 were used for analyses. Descriptive analysis of epidemiologic characteristics was used to report death cases following HepB. We used administered doses to calculate denominators to estimate the risk of death after vaccination. During 2013\u20132020, there were 161 deaths following the administration of 173 million doses of HepB, for an overall incidence of 0.9 deaths per million doses. One hundred fifty-seven deaths were categorized as coincidental, and four deaths were accompanied by an abnormal reaction determined to be unrelated to the cause of death. The most common causes of death were neonatal pneumonia and foreign body asphyxia. These data provide reliable evidence on the safety of HepB among infants in China and can enhance public confidence in HepB immunization. To ensure public confidence in infants\u2019 HepB vaccination, monitoring and scientifically evaluating AEFI-related deaths of HepB is necessary.<\/jats:p>","DOI":"10.3389\/fpubh.2023.1170483","type":"journal-article","created":{"date-parts":[[2023,6,16]],"date-time":"2023-06-16T05:59:55Z","timestamp":1686895195000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":1,"title":["Analysis of deaths following yeast-derived hepatitis B vaccination of infants, China, January 2013 to December 2020"],"prefix":"10.3389","volume":"11","author":[{"given":"Sihui","family":"Zhang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tianshuo","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Linyi","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mingzhu","family":"Xie","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qing-Bin","family":"Lu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Juan","family":"Du","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jing","family":"Zeng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ninghua","family":"Huang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yaqiong","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chao","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fuqiang","family":"Cui","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2023,6,16]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1186\/s12985-020-01393-z","article-title":"Disease burden of chronic hepatitis B and complications in China from 2006 to 2050: an individual-based modeling study","volume":"17","author":"Zheng","year":"2020","journal-title":"Virol J"},{"key":"ref2","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1016\/j.bpobgyn.2020.02.014","article-title":"Hepatitis B \u2013 vertical transmission and the prevention of mother-to-child transmission","volume":"68","author":"Cheung","year":"2020","journal-title":"Best Pract Res Clin Obstet Gynaecol"},{"key":"ref3","doi-asserted-by":"publisher","first-page":"1103","DOI":"10.1016\/S1473-3099(16)30327-9","article-title":"A hepatitis B-free generation in China: from dream to reality","volume":"16","author":"Fan","year":"2016","journal-title":"Lancet Infect Dis"},{"year":"2022","author":"Yuan","key":"ref4"},{"key":"ref5","doi-asserted-by":"publisher","first-page":"765","DOI":"10.3201\/eid2305.161477","article-title":"Prevention of chronic hepatitis B after 3 decades of escalating vaccination policy, China","volume":"23","author":"Cui","year":"2017","journal-title":"Emerg Infect Dis"},{"key":"ref6","doi-asserted-by":"publisher","first-page":"2818","DOI":"10.1097\/CM9.0000000000001791","article-title":"Elimination of hepatitis B virus infection in children: experience and challenge in China","volume":"134","author":"Tang","year":"2021","journal-title":"Chin Med J"},{"key":"ref7","doi-asserted-by":"publisher","first-page":"2992","DOI":"10.4161\/21645515.2014.971643","article-title":"Hepatitis B vaccine adverse events in China: risk control and regulation","volume":"10","author":"Meina","year":"2014","journal-title":"Hum Vaccin Immunother"},{"key":"ref8","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1016\/j.vaccine.2012.11.051","article-title":"Systematic review of reporting rates of adverse events following immunization: an international comparison of post-marketing surveillance programs with reference to China","volume":"31","author":"Guo","year":"2013","journal-title":"Vaccine"},{"key":"ref9","doi-asserted-by":"publisher","first-page":"4041","DOI":"10.1016\/j.vaccine.2015.04.060","article-title":"Surveillance of adverse events following immunization in China: past, present, and future","volume":"33","author":"Liu","year":"2015","journal-title":"Vaccine"},{"key":"ref10","first-page":"538","article-title":"Analysis on the surveillance of adverse events following immunization in China, 2007\u20132008","volume":"15","author":"Wu","year":"2009","journal-title":"Zhongguo Yi Miao He Mian Yi"},{"key":"ref11","doi-asserted-by":"publisher","first-page":"1279","DOI":"10.1001\/archpedi.153.12.1279","article-title":"Neonatal deaths after hepatitis B vaccine \u2013 the vaccine adverse event reporting system, 1991\u20131998","volume":"153","author":"Niu","year":"1999","journal-title":"Arch Pediatr Adolesc Med"},{"key":"ref12","doi-asserted-by":"publisher","first-page":"1182","DOI":"10.1016\/j.vaccine.2019.01.009","article-title":"Deaths reported to national surveillance for adverse events following immunization in China, 2010\u20132015","volume":"37","author":"Wu","year":"2019","journal-title":"Vaccine"},{"key":"ref13","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1016\/S0895-4356(98)00014-6","article-title":"Comparative safety of two recombinant hepatitis B vaccines in children: data from the vaccine adverse event reporting system (VAERS) and vaccine safety datalink (VSD)","volume":"51","author":"Niu","year":"1998","journal-title":"J Clin Epidemiol"},{"key":"ref14","doi-asserted-by":"publisher","first-page":"221","DOI":"10.3390\/vaccines9030221","article-title":"Allergic reactions to current available COVID-19 vaccinations: pathophysiology, causality, and therapeutic considerations","volume":"9","author":"Kounis","year":"2021","journal-title":"Vaccines (Basel)"},{"key":"ref15","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1016\/j.jaci.2012.04.003","article-title":"Adverse reactions to vaccines practice parameter 2012 update","volume":"130","author":"Kelso","year":"2012","journal-title":"J Allergy Clin Immunol"},{"key":"ref16","doi-asserted-by":"publisher","first-page":"1465","DOI":"10.1016\/j.jaci.2018.12.1003","article-title":"Anaphylaxis after vaccination reported to the vaccine adverse event reporting system, 1990\u20132016","volume":"143","author":"Su","year":"2019","journal-title":"J Allergy Clin Immunol"},{"key":"ref17","doi-asserted-by":"publisher","first-page":"868","DOI":"10.1016\/j.jaci.2015.07.048","article-title":"Risk of anaphylaxis after vaccination in children and adults","volume":"137","author":"McNeil","year":"2016","journal-title":"J Allergy Clin Immunol"},{"key":"ref18","doi-asserted-by":"publisher","first-page":"863","DOI":"10.1001\/jamapediatrics.2017.1743","article-title":"Early-life epilepsies and the emerging role of genetic testing","volume":"171","author":"Berg","year":"2017","journal-title":"JAMA Pediatr"},{"key":"ref19","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1097\/00019052-200404000-00011","article-title":"Genetics of the epilepsies","volume":"17","author":"Gutierrez-Delicado","year":"2004","journal-title":"Curr Opin Neurol"},{"key":"ref20","doi-asserted-by":"publisher","first-page":"994","DOI":"10.1111\/epi.13391","article-title":"Involvement of GATOR complex genes in familial focal epilepsies and focal cortical dysplasia","volume":"57","author":"Weckhuysen","year":"2016","journal-title":"Epilepsia"},{"key":"ref21","doi-asserted-by":"publisher","first-page":"1681","DOI":"10.1016\/j.jaci.2016.02.010","article-title":"Advances and highlights in mechanisms of allergic disease in 2015","volume":"137","author":"Wawrzyniak","year":"2016","journal-title":"J Allergy Clin Immunol"},{"key":"ref22","doi-asserted-by":"publisher","first-page":"S402","DOI":"10.1016\/j.jaci.2007.08.061","article-title":"9. Anaphylaxis","volume":"121","author":"Simons","year":"2008","journal-title":"J Allergy Clin Immunol"},{"key":"ref23","doi-asserted-by":"publisher","first-page":"956473","DOI":"10.3389\/fimmu.2022.956473","article-title":"Change in adverse event reporting following immunization of hepatitis B vaccine among infants between 2013 to 2020 before and after the vaccine administration law in China","volume":"13","author":"Wang","year":"","journal-title":"Front Immunol"},{"key":"ref24","doi-asserted-by":"publisher","first-page":"602","DOI":"10.4161\/hv.6.7.11933","article-title":"China's emerging vaccine industry","volume":"6","author":"Hendriks","year":"2010","journal-title":"Hum Vaccin"},{"key":"ref25","doi-asserted-by":"publisher","first-page":"441","DOI":"10.1093\/ije\/dyv349","article-title":"Loss of confidence in vaccines following media reports of infant deaths after hepatitis B vaccination in China","volume":"45","author":"Yu","year":"2016","journal-title":"Int J Epidemiol"},{"key":"ref26","doi-asserted-by":"publisher","first-page":"7728","DOI":"10.1016\/j.vaccine.2019.07.041","article-title":"An approach for preparing and responding to adverse events following immunization reported after hepatitis B vaccine birth dose administration","volume":"38","author":"Gidudu","year":"2020","journal-title":"Vaccine"},{"key":"ref27","doi-asserted-by":"publisher","first-page":"6550","DOI":"10.1016\/j.vaccine.2009.08.048","article-title":"Epidemiological serosurvey of hepatitis B in China-declining HBV prevalence due to hepatitis B vaccination","volume":"27","author":"Liang","year":"2009","journal-title":"Vaccine"}],"container-title":["Frontiers in Public Health"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fpubh.2023.1170483\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,6,16]],"date-time":"2023-06-16T05:59:57Z","timestamp":1686895197000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fpubh.2023.1170483\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,6,16]]},"references-count":27,"alternative-id":["10.3389\/fpubh.2023.1170483"],"URL":"https:\/\/doi.org\/10.3389\/fpubh.2023.1170483","relation":{},"ISSN":["2296-2565"],"issn-type":[{"type":"electronic","value":"2296-2565"}],"subject":[],"published":{"date-parts":[[2023,6,16]]},"article-number":"1170483"}}